Trial Profile

A Phase 2 proof-of-concept study of SCY-770 in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 15 Oct 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Oct 2026 According to SCYNEXIS media release, Pharmacokinetic data from phase 1 study and prior studies will inform dose selection for the Phase 2 trial in patients with ADPKD, which remains on track to initiate in the fourth quarter of 2026.
28 Sep 2026 According to SCYNEXIS media release, The Company does not anticipate any changes to its previously communicated guidance regarding development milestones for SCY-770, its lead product candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD), or the Companys cash runway into 2029.
10 Aug 2026 According to SCYNEXIS media release, the company remains on track to initiate the trial in Q4 2026, with an anticipated early efficacy readout in the second half of 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com